Review Article

The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Pandemic: Are Africa’s Prevalence and Mortality Rates Relatively Low?

Solomon H. Mariam

Infectious Diseases Program, Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia

Correspondence should be addressed to Solomon H. Mariam; solomon.habtemariam@aau.edu.et

Received 8 December 2021; Revised 14 January 2022; Accepted 28 January 2022; Published 26 February 2022

1. Introduction

Since late 2019, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of COVID-19, has plagued the world. At smaller scales, the world had previously experienced at least two respiratory viral epidemics since 2000. These were SARS-CoV-1, which emerged in China in 2003, and Middle East respiratory syndrome (MERS) in 2009-10. SARS-CoV-2 has proven that it can infect many millions and kill several millions.

Infected persons can have variable immune responses. Disease may vary from mild symptoms to severe pneumonia, respiratory failure, to death. Several factors including age, presence of comorbidities, environmental factors, and genetics contribute to the final outcome of the disease. Asymptomatic carriers can also spread the infection as they shed the virus [1].

SARS-CoV-2 contains structural proteins called M (membrane), E (envelope), and S (spike) proteins embedded in the viral envelope and a nucleocapsid (N) protein, which embeds the viral RNA in the inner core. The spike protein S binds through its receptor-binding domain (RBD) to its receptor angiotensin-converting enzyme 2 (ACE2) found on human cells [2, 3]. ACE2 is found on multiple organs including the lungs, heart, and kidneys. In the lungs, ACE2 is found on type II pneumocytes, the cells that are found on
lung alveoli and that secrete surfactant needed for surface tension reduction and lung expansion during breathing. The bound viral S protein is then subsequently cleaved into two subunits: S1, the receptor-binding subunit, and S2, the membrane fusion subunit by the host cell protease TMPRSS2 resulting in fusion with the host cell membrane and entry into host cells, which initiates the subsequent pathology. SARS-CoV-2 invades larger surface area of the lung. It has a high affinity, even higher than that of SARS-CoV-1, for its receptor ACE2 [3]. SARS-CoV-1, MERS, and a bat coronavirus also use ACE2 as their receptor to enter human host cells [4, 5].

There can be several hallmarks of COVID-19. Excessive inflammatory responses involving multiple organs contribute to high morbidity and mortality. COVID-19 causes fluid accumulation in alveoli, causing reduced oxygen to reach blood. This leads to shortness of breath, tachypnea, and organ damage. Collectively, these are manifestations of acute respiratory distress syndrome (ARDS). It may also cause cardiovascular disease due to inflammatory cytokine surge [6, 7]. Unfavorable outcome in COVID-19 patients may also be caused by downregulation of ACE2, which otherwise has a protective role by reducing both vascular permeability and inflammation of the lungs and other tissues [8]. Formation of thrombus, which contributes to patient morbidity and mortality, is common in patients with the disease [9, 10]. COVID-19 also causes diffuse pulmonary intravascular coagulopathy in the lungs of COVID-19 patients [6].

2. Global Occurrence of SARS-CoV-2 Infections and COVID-19

Epidemics or pandemics are not new, but this pandemic is prominent in the magnitude of the economic and human life losses it is causing. In comparative terms, Africa seems to have slower rates of infectious cases and mortality. Supplementary Figure 1 (S.F.1.) depicts total cases and deaths, including per million populations, caused by the pandemic in countries from selected regions of five continents. The information in this table was obtained from Worldometers (accessed, January 6, 2022). From the data in S.F.1, it can be argued that not only Africa, but also Asia has the fewest number of COVID-19 deaths. Asia is the continent where the world’s population giants are located. However, some Asian countries, such as Mongolia, Indonesia, Philippines, Nepal, and India, have been affected much more than other Asian countries, with deaths per million ranging from 345 in India to more than 600 in Mongolia. In Oceania, French Polynesia and Fiji have the highest rates of deaths per million, as the Worldometers data show. In S.F.1, it is of note that numerical values do not always convey the meaning or impact. Total cases and population sizes are also considered. For example, looking at S.F.1 D, it appears that both Seychelles and Germany have similar rates of deaths/million. However, the population sizes of the two countries are vastly different, being more than 80 million for Germany but about hundred thousand for Seychelles.

Furthermore, it is important to consider the age structures of populations of countries when evaluating the deaths/million. It is known that mortality due to the pandemic is highest in older age groups and, accordingly, some countries with pyramidal population age structures, which is especially true in most African countries, may appear to have lower death rates than countries having populations with higher median ages [11]. Higher death rates in infected people often happen to be associated with other comorbidities, which also often occur in older age groups.

3. The African Continent and SARS-CoV-2

Data seem to indicate the prevalence of infection or death rates due to COVID-19 are comparatively low in Africa. There have been several hypotheses forwarded, suggesting the factors responsible for the comparatively low infection and death rates in Africa. These include BCG vaccination, weather conditions less favorable for viral transmission in Africa, previous malaria infection, and genetic factors. In the following paragraphs, published information on the proposed hypotheses is discussed.

3.1. BCG Vaccination. Africa as a whole adopts BCG vaccination programs to the new borne. Globally, the BCG vaccination policies of countries differ from those that never adopted it, such as France, Spain, and England, to those that once had the program but not anymore, such as Israel, to those that currently vaccinate but without a booster follow-up, such as the whole of Africa, Russia, and Middle and Far East countries [[12], Figure 1]. There are reports that BCG vaccination boosts immune response against COVID-19. Cross-reactive epitopes have been found to be shared between B and T cell epitopes of BCG and B and T cell epitopes of SARS-CoV-2 [13], with implications that these could lead to adaptive immune responses against SARS-CoV-2 in BCG-vaccinated individuals.

A study [14] compared mortality rates due to the current pandemic among the above three groups of countries. Their finding was that the median mortality rates per million ranged from 146.5 to 34 to 2.1, respectively, in the three groups of countries. Another early 2020 study [15] on the same similarly concluded that BCG vaccination history and death per million are negatively correlated, and the protection was long-lasting. These authors also argue that countries that only previously had BCG vaccination programs or that never implemented such programs had higher death rates than countries with current BCG vaccination programs, and the inverse correlations remained intact after controlling for confounding factors; that is, the inverse relationships were maintained in countries with similar socioeconomic conditions.

There are inconsistencies in efficacy of BCG vaccination in protecting COVID-19. For example, a following study [16] reported that the negative correlation described in the previous study [15] was no longer observed after April 2020. Kandeil et al. [17] reported that BCG and other childhood vaccines did not provide protective or neutralizing antibodies against SARS-CoV-2 in mice.
Some of the above discordant results could be attributable to several interacting factors, including (i) variations in study designs and possible bias also created with selection of study participants; (ii) the route of administration, i.e., whether it is oral, subcutaneous, intradermal, etc.; (iii) age at administration, previous exposure, coinfections [12, 18, 19]; (iv) probable differences in medical interventions, whether palliative or otherwise that can possibly impact on the outcome; (v) differences in the specific BCG strain used for immunization, i.e., whether BCG Pasteur, Russia, Danish, etc. were used. In connection to this specific BCG strain factor, a recent study [20] compared five licensed BCG vaccine strains with respect to their viability in culture and cytokine induction patterns and found that the BCG vaccines markedly differed in viability in culture and induction of chemokines and cytokines. BCG immunization data are also generally country-level, and these may not necessarily translate to individual patient-level data.

Further, some issues can be raised regarding the supposed protective effect of BCG against SARS-CoV-2. Countries such as New Zealand and Australia that do not currently have BCG vaccination programs have relatively low cases of infection and mortality. These countries initially had minimal infection rates because they are island nations and also instituted border closures and public-private public health measures. However, they have been recently hit by the more transmissible Delta and/or Omicron variants. Conversely, countries that have BCG vaccination programs, such as India and Brazil, have high rates of infection. It is also important to distinguish between two aspects of the supposed BCG effect: reductions in infection and mortality from COVID-19. These emerging BCG stories deserve serious consideration, and this pandemic has indeed given renewed interest for intensified clinical trials on BCG that are currently ongoing.

### 3.2. Temperature and Humidity

Low relative humidity (RH) and low temperature promote transmission, while high temperature and humidity within a certain range contribute to reduced transmission [21–25]. The seasonality of influenza viruses in temperate regions is well recognized [26]. Low AH and influenza usually co-occur during temperate Winters. Both viral stability and transmissibility are important. Low AH promotes influenza virus survival, transmission, and influenza-related deaths, because inhalation of dry air also impairs innate resistance and virus clearance [26–29]. In temperate Winters, low temperatures and both low and high RH permit survival of SARS-CoV-2 [25]. Besides, indoor air conditioning with low humidity and poor ventilation may also promote transmission [25].

Studies observed that SARS-CoV-2 could be inactivated by sunlight. High temperatures can cause decay of the virus and shorten its half-life, with reduced infectivity. Sunlight also inactivates SARS-CoV-2 on surfaces [30–32]. Indoor conditions can promote fomite and aerosol transmission. Decay of SARS-CoV-2 was accelerated when temperature and RH increase [32]. In outdoor conditions of intense sunlight, transmission of influenza and SARS-CoV-2 viruses would be reduced, depending on viral load and infectious dose [31–33]. Ultraviolet radiation causes viral inactivation and reduction of its reproduction numbers [33–36]. However, high infection rates have occurred at high temperatures, indicating the importance of combinations of infection control measures [35, 37, 38].

Other respiratory viruses can also be sensitive to high temperatures. Conversely, low temperatures favor transmission [24–26]. High temperature and humidity reduced transmission of SARS-CoV-1 and influenza virus [39, 40]. There is negative correlation between both AH and temperature and influenza viruses A and B [41]. Cold temperatures and low humidity favor transmission of the virus because of increased risk of respiratory tract infections.
antibodies against SARS-CoV-2 with not only antigens. Vanroye et al. [50] found similar cross-reactivity of Plasmodium vivax between SARS-CoV-2 and Plasmodium falciparum. Finally, how many of those in malaria-endemic regions of Africa. This phenomenon is also thought to develop in hosts previously exposed to other bacteria or viral infections. It is referred to as cross immunity [53]. However, it is important to note that there are non-African countries with low numbers of SARS-CoV-2 infection and that were free of malaria. Thus, malaria can be ruled out as having any role in the epidemiology of the pandemic in those countries. Finally, how many of those with SARS-CoV-2 infections in Africa had malaria and how many of those were spared need to be tested, after adjusting for any comorbidities.

Chloroquine and hydroxychloroquine are drugs that have been used for treatment of malaria. These drugs had been proposed as possible prophylactic or therapeutic drugs against SARS-CoV-2-based on previous knowledge that these drugs showed inhibitory effects in vitro against some common viruses infectious to humans. However, several recent studies or systematic reviews concluded that the drugs have no therapeutic value in preventing or treating SARS-CoV-2 infections in humans, probably because tolerable therapeutic serum concentrations cannot be achieved in vivo [54–56].

3.4. Vitamin D Levels. Several studies indicated that vitamin D supplementation could benefit SARS-CoV-2 control measures [57–60]. Vitamin D deficiency increased risk to severe SARS-CoV-2 infection outcomes and admission to ICUs in persons with vitamin D deficiency. Conversely, the need for admission to ICU was reduced in patients after administration of calcifediol, a vitamin D analog that helps in metabolism of calcium [61–63]. Other reports suggested that vitamin D levels in African populations are generally low [61, 64, 65]. Therefore, this phenomenon does not favor the idea of lower rate of SARS-CoV-2 infection prevalence in Africa attributable to vitamin D, but possible factors other than vitamin D contribute to the protection. It may also be that its benefit is reduced due to presence of comorbidities. Controlled trials are needed to clarify this ambiguity. The general consensus is to give vitamin D supplementation to vitamin D-deficient patients, given the indirect evidence of its benefit for optimal immune function and the relative safety of its administration [66, 67].

3.5. Genetic/Metabolic Factors

3.5.1. Chromosome 3. A genetic basis for susceptibility to SARS-CoV-2 infection has been put forward. Two studies [68, 69] found that carriage of a 6-gene cluster on chromosome 3 is a risk factor and associated with the severity of SARS-CoV-2 infection and respiratory failure. This gene cluster was inherited from Neanderthals (ancient hominids) [69]. These gene clusters are almost completely absent from Africa, consistent with the idea that gene flow from Neanderthals into African populations was limited [69]. A region of chromosome 3, i.e., 3p21.31, containing 12 protein-coding genes may be involved in SARS-CoV-2 pathogenesis when it carries single nucleotide polymorphisms (SNPs) in its variant form. This variant enhances complement fixation and infiltration of lung tissues with monocytes and macrophages in infected cases (a hallmark of severe disease), resulting in severe inflammatory responses [70, 71].

3.5.2. Gene Polymorphisms. A German study [72] analyzed SNP variants of TMPRSS2, which included rs2070788, rs383510, and rs12329760. Of these, only rs383510 was
associated with increased risk (~2-fold) of infection or disease severity. However, allele variants of both rs2070788 and rs383510 were shown to be significantly associated with susceptibility to infection by H1N1 and H7N9 influenza viruses in Chinese patients [73]. It appears that these variants are expressed, alternatively or to variable degrees, in different ethnic populations. The allele frequencies of these variants are comparatively lower in Africans than in Europeans and East Asians [72].

The expression level of ACE2 and TMPRSS2, or allele frequencies of their variants, was found to be significantly lower in African people of both genders than in Europeans and East and South Asians [74]. Another study [75] found strong correlation between case fatality rate and SNPs in several relevant genes including other polymorphisms in TMPRSS2 and ACE2. An inhibitor of TMPRSS2 that has been found to block entry of SARS-CoV-2 might offer a therapeutic option [2].

3.5.3. Alpha (α)-1 Antitrypsin. Studies implicate α-1 antitrypsin deficiency (a recessive, heritable disease) in exacerbating coronavirus disease. α-1 antitrypsin is produced by hepatocytes and secreted into the blood. It acts as a circulating serine protease inhibitor, and its principal target is the protease neutrophil elastase, which is released by damaged neutrophils [76]. α-1 antitrypsin protects the lungs and other tissues containing elastin. The normal allele is PiM. Many genetic variants (alleles) of α-1 antitrypsin cause α-1 antitrypsin deficiency. The most common variant alleles are PiS and PiZ. Most (96%) of α-1 antitrypsin deficiency is linked to the PiZZ type, causing very low α-1 antitrypsin production, while the other variants produce low-intermediate levels [76–78]. The deficiency can also make people susceptible to developing asthma, bronchitis, chronic obstructive pulmonary disease, etc. The number of deaths due to the current pandemic and prevalence of α-1 antitrypsin deficiency are strongly positively correlated in many countries [78, 79].

Recent studies on the global epidemiology of α-1 antitrypsin deficiency revealed that Africa as a whole has the lowest rates of these deficiency alleles. In North Africa, several countries were reported to have no PiS or PiZ prevalence. Several central and south African countries have PiS frequencies ranging from 1.8 to 63 per 1,000 population. In other African countries, the predominant allele was generally the milder form, and the PiZ frequency is very low or absent [76, 77]. Some regions of eastern and western Africa were found to have moderate frequencies of PiZ allele [80]. In European countries, both alleles are found at variable frequencies, e.g., 2.0 in Greece to a high of 76 per 1,000 population in France [77]. Countries in Europe with the highest rates of SARS-CoV-2 disease and death were also those with the highest rates of alleles causing α-1 antitrypsin deficiency, as previously shown [81]. In North and Central American countries, both alleles were found in all countries, but the PiS allele is predominant, being 23 to 45 per 1,000 population. In Asia, the prevalence of the two alleles is generally low to medium, ranging from 1.0 to 31 for PiS and 0.2 to 15.0 for PiZ. Of note, Indonesia, Mongolia, and Nepal have zero prevalence of both alleles, while China has a prevalence of 1.0 and 0.0 per 1,000 population for PiS and PiZ, respectively. In Australia and New Zealand, the prevalence of PiS is 42 and 12, while the prevalence of PiZ is 33 and 26, respectively, per 1,000 population [76, 77].

3.5.4. C-Reactive Protein (CRP). Elevated levels of CRP have also been implicated as a marker of COVID-19 disease severity in patients. The CRP is produced in the liver in response to increased inflammatory cytokines such as interleukin-6 (IL-6), and levels of these two biomarkers are positively correlated [82]. CRP release is associated with conditions such as hypertension, obesity, cardiovascular disease, and ARDS, or infections with influenza viruses such as H1N1, MERS, and SARS-CoV-2 [83–85]. Recent studies indicate that CRP levels in COVID-19 patients who were severely ill or died were significantly higher than those in surviving patients [86, 87]. Elevated CRP levels during the first 2–3 days of hospital admission can be used prospectively as predictors to identify those patients who would deteriorate to respiratory failure and require intensive care, including intubation [82, 88].

Studies of CRP levels in association with COVID-19 in Africa appear to be rare, but the metabolic marker may not be rare. Some reports indicated that CRP levels were associated with adverse outcomes in patients [89–91]. In general, CRP levels are high in many African countries or in African Americans, especially in association with diabetes, hypertension, or infectious diseases [92].

3.5.5. Blood Type. ABO blood groups have been suggested to be associated with outcomes of infection with other viruses or bacteria, e.g., type O being more susceptible to Norwalk virus, Helicobacter pylori or SARS-CoV-1 [93–95]. Some reports indicate that blood type A is more susceptible to SARS-CoV-2 infection. These suggest that the RBD of SARS-CoV-2 preferentially binds to type A antigens specifically located on human lung epithelial cells [96]. Still, reported results regarding blood type susceptibility to SARS-CoV-2 are conflicting—some reporting type A, though more susceptible, do not need intubation, and type O has the lowest risk [97]. In Africans, type A is reported to be at low risk, while type O occurs at the highest frequency [98].

Prevalence of disease relative to blood type should be adjusted to known prevalence of blood types in the general population since proportions of blood types in patients may not be representative of the actual proportions in the general populations. Similarly, blood type distributions show variability in different races. Furthermore, presence of other comorbidities may influence or override blood type susceptibility. Most studies also suffer from insufficient sample sizes. Studies based on large samples indicate no associations of blood types to infection or COVID-19 severity, or only speculate that type O may be associated with a lower risk, while type A may be associated with a higher risk [99, 100]. This blood type-COVID-19 interaction also awaits further clarification.
4. Role of Geographic Location, Race, and Ethnicity in the Spread of the Global Pandemic

Studies show that this pandemic hits differentially at continental, country, and at subcountry levels [101]. Studies in the United States indicated that the distribution of the pandemic exhibited disparities based on geography, resulting in differential exposure risk, testing rates, and access to health services. These studies also show that the disparities based on geography intermingle with other factors such as race, ethnicity, and age to contribute to the disparities. Zalla et al. [102] argue that geography in relation to race, including where one lives and works, should be considered because race- and ethnicity-based desegregation have created the geographical landscapes where people have increased risks (e.g., poor housing, sanitation, working conditions, and access to health care) to be exposed, infected, and possibly die from the infection. In a retrospective cohort study of more than 19,000 patients in the United States, mortality—both crude and after adjustment for demographic factors and comorbidities—was found to be slightly higher in African-American patients than White patients [103]. Others found similar results and showed that once infected with SARS-CoV-2, African-American patients were at significantly higher odds to require hospitalization and to die than White patients [104–106]. Furthermore, African-Americans are reported to have higher rates of comorbidities such as diabetes and hypertension. But, one study found adjusted mortality rate to be lower for African-Americans [107]. Hospitalization and mortality rates in Hispanics were reported to be mostly similar to those of African-Americans, but there are some conflicting results. A more recent study regarding vaccination further indicated that priority should have been hit worse by this pandemic. There are some suggested reasons for the “low” rates. One is that many African countries responded timely to control the pandemic by travel restrictions, limited international connections, school closures, etc. The other is the age factor. Africa has the youngest population globally. This seems reasonable, since older age groups are the worst affected. For example, in Chile, publicly available data showed that senior citizens over 70 years of age had the highest case fatality rates even though younger age groups had the highest number of cases [116]. In New York, infection fatality risk was more than 100-fold higher in people ≥75 years during the first wave [117]. Similarly, a nationwide study in Spain showed infection fatality risk increased sharply in people over 50 years [118]. Such increasing mortality rates in older age groups were also observed in seven other economically advanced countries [119].

5. The African “Paradox”

The rates of cases and COVID-19 fatalities in Africa are believed to be low. Some call this paradoxical, as if Africa should have been hit worse by this pandemic. There are some suggested reasons for the “low” rates. One is that many African countries responded timely to control the pandemic by travel restrictions, limited international connections, school closures, etc. The other is the age factor. Africa has the youngest population globally. This seems reasonable, since older age groups are the worst affected. For example, in Chile, publicly available data showed that senior citizens over 70 years of age had the highest case fatality rates even though younger age groups had the highest number of cases [116]. In New York, infection fatality risk was more than 100-fold higher in people ≥75 years during the first wave [117]. Similarly, a nationwide study in Spain showed infection fatality risk increased sharply in people over 50 years [118]. Such increasing mortality rates in older age groups were also observed in seven other economically advanced countries [119].

6. Is South Africa an Outlier?

South Africa is regarded as an outlier in Africa by many. In South Africa, several SARS-CoV-2 lineages with unique mutations were identified during the first wave, and most of these lineages had spread widely before lockdown and travel restrictions were imposed [120]. Rapid transmission also continued in South Africa from imported cases down to the community even during lockdown [121]. South Africa experienced very high mortality during both the first and second waves, but most African countries also had higher second-wave deaths [122]. In a South African study, human immunodeficiency virus and tuberculosis infections were associated with a 2-fold increase COVID-19 mortality [123]. South Africa has the highest number of total deaths, but it is exceeded by Tunisia in the number of deaths/million people. Botswana, Seychelles, and Libya also have the highest numbers of COVID-19 deaths per million in Africa (but less
than South Africa). Finally, it is of note that testing and reporting capacities differ among countries.

7. Conclusions

It is important to know the role(s) of malaria, BCG vaccination, BCG strain type, blood type, age group, genetic background, comorbidities, etc., and their interactions when one is superimposed over the others. Effects of sunlight, high temperatures, and UV in reducing survival and transmissibility of the virus, even if positive, may be masked by other risk factors. It may also be too early to speak of low rates of the infection or mortality in Africa because the pandemic is still spreading. The available evidence calls for more randomized, controlled studies that take into account all possible variables. The suggested protective effects by BCG, weather, etc. cannot substitute other preventive measures such as face masks, ventilation, and physical distances; fortunately all of them are relatively inexpensive and effective when combined. The microbiome may also play a role in these complex interactions and needs to be explored. Furthermore, the changing variants of SARS-CoV-2 might bring in different responses in African or other populations. Another point is that most of the studies in the published literature were not done in African context.

In a continent where only a small percentage of the population has been tested due to limited testing capacity, perhaps many of those who are infected but do not show any symptoms, or show only mild symptoms, harbor the true burden of the infection in Africa. Low rates of testing and underreporting lead to underestimation of the true cases, mortality rates, and contribute to further transmissions. Seroprevalence surveys in otherwise healthy people have also shown that these exceed those reported after molecular tests were conducted. Some symptoms that overlap among influenza, the common cold, pneumonia, and SARS-CoV-2 infection could mislead people to consider such symptoms as usual. Likewise, there can be COVID-19 deaths that are mistakenly attributed for other causes. Rates of infection are increasing from time to time in some African countries, suggesting that it is still early to speak of Africa as having low rates of infection and mortality from COVID-19.

Data Availability

All data have been included in the manuscript and supplementary material.

Conflicts of Interest

The author declares that there are no conflicts of interest.

Supplementary Materials

Supplementary Figure 1. Reported COVID-19 cases and deaths per million populations for selected countries from 5 continents can be found online. (Supplementary Materials)

References

[1] M. Gandhi, D. S. Yokoe, and D. V. Havlir, "Asymptomatic transmission, the achilles’ heel of current strategies to control COVID-19," New England Journal of Medicine, vol. 382, no. 22, pp. 2158–2160, 2020.
[2] M. Hoffmann, H. Kleine-Weber, S. Schroeder et al., “SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor,” Cell, vol. 181, no. 2, pp. 271–280, 2020.
[3] J. Shang, G. Ye, K. Shi et al., "Structural basis of receptor recognition by SARS-CoV-2," Nature, vol. 581, no. 7807, pp. 221–224, 2020.
[4] W. Li, M. J. Moore, N. Vasileva et al., "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus," Nature, vol. 426, no. 6965, pp. 450–454, 2003.
[5] J. H. Kuhn, W. Li, H. Choe, and M. Farzan, "Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus," Cellular and Molecular Life Sciences: CMLS, vol. 61, pp. 2738–2743, 2004.
[6] D. McGonagle, J. S. O’Donnell, K. Sharif, P. Emery, and C. Bridgewood, “Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia," Lancet Rheumatology, vol. 2, no. 7, pp. e437–e445, 2020.
[7] R. Kawakami, A. Sakamoto, K. Kawai, A. Gianatti, D. Pellegrini, and A. Nasr, "Pathological evidence for SARS-CoV-2 as a cause of myocarditis," Journal of the American College of Cardiology, vol. 77, no. 3, pp. 314–325, 2021.
[8] U. Kaur, K. Acharya, R. Mondal et al., "Should ACE2 be given a chance in COVID-19 therapeutics: a semi-systematic review of strategies enhancing ACE2," European Journal of Pharmacology, vol. 887, Article ID 173545, 2020.
[9] T. C. Hanfl, A. M. Mohareb, J. Giri, J. B. Cohen, and J. A. Chirinos, "Thrombosis in COVID-19," American Journal of Hematology, vol. 95, no. 12, pp. 1578–1589, 2020.
[10] J. Avila, B. Long, D. Holladay, and M. Gottlieb, "Thrombotic complications of COVID-19," The American Journal of Emergency Medicine, vol. 39, pp. 213–218, 2021.
[11] J. B. Dowd, L. Andriano, D. M. Brazel et al., "Demographic science aids in understanding the spread and fatality rates of COVID-19," Proceedings of the National Academy of Sciences, vol. 117, no. 18, pp. 9696–9698, 2020.
[12] A. Zwerling, M. A. Behr, A. Verma, T. F. Brewer, D. Menzies, and M. Pai, "The BCG world atlas: a database of global BCG vaccination policies and practices," PLoS Medicine, vol. 8, no. 3, Article ID e1001012, 2011.
[13] S. Urbán, G. Paragi, K. Burian, G. R. McLean, and D. P. Virok, "Identification of similar epitopes between severe acute respiratory syndrome coronavirus-2 and Bacillus Calmette-Guérin: potential for cross-reactive adaptive immunity," Clinical & Translational Immunology, vol. 9, no. 12, Article ID e1227, 2020.
[14] R. Ebina-Shibuya, N. Horita, H. Namkoong, and T. Kaneko, "National policies for paediatric universal BCG vaccination were associated with decreased mortality due to COVID-19," Respiratory, vol. 25, no. 8, pp. 898–899, 2020.
[15] L. E. Escobar, A. Molina-Cruz, and C. Barillas-Mury, "BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)," Proceedings of the National Academy of Sciences, vol. 117, no. 30, pp. 17720–17726, 2020.
[16] C. S. Lindestam Arlehamn, A. Sette, and B. Peters, "Lack of evidence for BCG vaccine protection from severe COVID-19," Proceedings of the National Academy of Sciences, vol. 117, no. 41, pp. 25203–25204, 2020.
[17] A. Kandeil, M. R. Gomaa, A. El Taweel et al., “Common childhood vaccines do not elicit a cross-reactive antibody response against SARS-CoV-2,” *PLoS One*, vol. 15, no. 10, Article ID e0241471, 2020.

[18] R. Tanner, B. Villarreal-Ramos, H. M. Vordermeier, and H. McShane, “The humoral immune response to BCG vaccination,” *Frontiers in Immunology*, vol. 10, Article ID 1317, 2019.

[19] D. Klinger, I. Blass, N. Rappoport, and M. Linial, “Significantly improved COVID-19 outcomes in countries with higher BCG vaccination coverage: a multivariable analysis,” *Vaccines*, vol. 8, no. 3, Article ID 378, 2020.

[20] A. Angelidou, M.-G. Conti, J. Diray-Arce et al., “Licensed Bacille Calmette-Guérin (BCG) formulations differ markedly in bacterial viability, RNA content and innate immune activation,” *Vaccine*, vol. 38, no. 9, pp. 2229–2240, 2020.

[21] A. C. Lowen, S. Mubareka, J. Steel, and P. Palese, “Influenza virus transmission is dependent on relative humidity and temperature,” *PLoS Pathogens*, vol. 3, no. 10, pp. e151–1476, 2007.

[22] A. C. Lowen and J. Steel, “Roles of humidity and temperature in shaping influenza seasonality,” *Journal of Virology*, vol. 88, no. 14, pp. 7692–7695, 2014.

[23] N. Pica and N. M. Bouvier, “Environmental factors affecting the transmission of respiratory viruses,” *Current Opinion in Virology*, vol. 2, no. 1, pp. 90–95, 2012.

[24] Y. Ma, S. Pei, J. Shaman, R. Dubrow, and K. Chen, “Role of meteorological factors in the transmission of SARS-CoV-2 in the United States,” *Nature Communications*, vol. 12, no. 1, Article ID 3602, 2021.

[25] D. H. Morris, K. C. Yinda, A. Gamble et al., “Mechanistic theory predicts the effects of temperature and humidity on inactivation of SARS-CoV-2 and other enveloped viruses,” *bioRxiv*, vol. 18, Article ID 341883, 2021.

[26] M. Moriyama, W. J. Hugentobler, and A. Iwasaki, “Seasonality of respiratory viral infections,” *Annual Review of Virology*, vol. 7, no. 1, pp. 83–101, 2020.

[27] J. Shaman and M. Kohn, “Absolute humidity modulates influenza survival, transmission, and seasonality,” *Proceedings of the National Academy of Sciences*, vol. 106, no. 9, pp. 3243–3248, 2009.

[28] J. Shaman, V. E. Pitzer, C. Viboud, B. T. Grenfell, and M. Lipsitch, “Absolute humidity and the seasonal onset of influenza in the continental United States,” *PLoS Biology*, vol. 8, no. 2, Article ID e1000316, 2010.

[29] E. Kudo, E. Song, L. J. Yockey et al., “Low ambient humidity impairs barrier function and innate resistance against influenza infection,” *Proceedings of the National Academy of Sciences*, vol. 116, no. 22, pp. 10905–10910, May 2019.

[30] L. C. Marr, J. W. Tang, J. Van Mullekom, and S. S. Lakdawala, “Mechanistic insights into the effect of humidity on airborne influenza virus survival, transmission and incidence,” *Journal of The Royal Society Interface*, vol. 16, no. 150, Article ID 20180298, 2019.

[31] S. Ratnesar-Shumate, G. Williams, B. Green et al., “Simulated sunlight rapidly inactivates SARS-CoV-2 on surfaces,” *The Journal of Infectious Diseases*, vol. 222, no. 2, pp. 214–222, 2020.

[32] J. Biryukov, I. A. Boydston, R. A. Dunning et al., “SARS-CoV-2 is rapidly inactivated at high temperature,” *Environmental Chemistry Letters*, vol. 19, no. 2, pp. 1773–1777, 2021.

[33] M. Schuit, S. Gardner, S. Wood et al., “The influence of simulated sunlight on the inactivation of influenza virus in aerosols,” *The Journal of Infectious Diseases*, vol. 221, no. 3, pp. 372–378, 2019.

[34] N. G. Jablonski and G. Chaplin, “Human skin pigmentation as an adaptation to UV radiation,” *Proceedings of the National Academy of Sciences*, vol. 107, no. 2, pp. 8962–8968, 2010.

[35] J. L. Sagripanti and C. D. Lyle, “Estimated inactivation of coronaviruses by solar radiation with special reference to COVID-19,” *Photochemistry and Photobiology*, vol. 96, no. 4, pp. 731–737, 2020.

[36] S. Metelmann, K. Pattini, L. Brierley et al., “Impact of climatic, demographic and disease control factors on the transmission dynamics of COVID-19 in large cities worldwide,” *One Health*, vol. 12, Article ID 100221, 2021.

[37] T. Carleton, J. Cornetet, P. Huybers, K. C. Meng, and J. Proctor, “Global evidence for ultraviolet radiation decreasing COVID-19 growth rates,” *Proceedings of the National Academy of Sciences*, vol. 118, no. 1, Article ID e2012370118, 2021.

[38] R. E. Baker, W. Yang, G. A. Vecchi, C. J. E. Metcalf, and B. T. Grenfell, “Susceptible supply limits the role of climate in the early SARS-CoV-2 pandemic,” *Science*, vol. 369, no. 6501, pp. 315–319, 2020.

[39] K. Lin, D. Yee-tak Fong, B. Zhu, and J. Karlberg, “Environmental factors on the SARS epidemic: air temperature, passage of time and multiplicative effect of hospital infection,” *Epidemiology and Infection*, vol. 134, no. 2, pp. 223–230, 2006.

[40] K. H. Chan, J. S. M. Peiris, S. Y. Lam, L. L. M. Poon, K. Y. Yuen, and W. H. Seto, “The effects of temperature and relative humidity on the viability of the SARS coronavirus,” *Advances in Virology*, vol. 2011, Article ID 734690, 7 pages, 2011.

[41] A. Peci, A.-L. Winter, Y. Li et al., “Effects of absolute humidity, relative humidity, temperature, and wind speed on influenza activity in Toronto, Ontario, Canada,” *Applied and Environmental Microbiology*, vol. 85, no. 6, Article ID e02426-18, 2019.

[42] T. M. Mäkinen, R. Juvonen, J. Jokelainen et al., “Cold temperature and low humidity are associated with increased occurrence of respiratory tract infections,” *Respiratory Medicine*, vol. 103, no. 3, pp. 456–462, 2009.

[43] L. M. Casanova, S. Jeon, W. A. Rutala, D. J. Weber, and M. D. Sobsey, “Effects of air temperature and relative humidity on coronavirus survival on surfaces,” *Applied and Environmental Microbiology*, vol. 76, no. 9, pp. 2712–2717, 2010.

[44] H. Yuan, S. C. Kramer, E. H. Y. Lau, B. J. Cowling, and W. Yang, “Modeling influenza seasonality in the tropics and subtropics,” *PLoS Computational Biology*, vol. 17, no. 6, Article ID e1009050, 2021.

[45] W. Yang, S. Elankumaran, and L. C. Marr, “Relationship between humidity and influenza A viability in droplets and implications for influenza’s seasonality,” *PLoS One*, vol. 7, no. 10, Article ID e46789, 2012.

[46] J. Prévost, J. Richard, R. Gasser et al., “Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2,” *Journal of Biological Chemistry*, vol. 297, no. 4, Article ID 101151, 2021.

[47] S. Y. Gong, D. Chatterjee, J. Richard et al., “Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity,” *Virology*, vol. 563, pp. 134–145, 2021.
a modelling study,” *Lancet (London, England)*, vol. 391, no. 10127, pp. 1285–1300, 2018.

[49] A. C. Lowen, J. Steel, S. Mubareka, and P. Palese, “High temperature (30°C) blocks aerosol but not contact transmission of influenza virus,” *Journal of Virology*, vol. 82, no. 11, pp. 5650–5652, 2008.

[50] F. Vanroye, D. V. d. Bossche, I. Brosius, B. Tack, M. V. Esbroeck, and J. Jacobs, “COVID-19 antibody detecting rapid diagnostic tests show high cross-reactivity when challenged with pre-pandemic malaria, schistosomiasis and dengue samples,” *Diagnostics*, vol. 11, no. 7, Article ID 1163, 2021.

[51] M. Rusmini, P. Uva, A. Amoroso, M. Tolomeo, and A. Cavall, “How genetics might explain the unusual link between malaria and COVID-19,” *Frontiers in Medicine*, vol. 8, Article ID 650231, 2021.

[52] M. A. M. Jesa, M. E. M. Osman, M. A. Hassan et al., “SARS-CoV-2 and Plasmodium falciparum common immunodominant regions may explain low COVID-19 incidence in the malaria-endemic belt,” *New Microbes and New Infections*, vol. 38, Article ID 100817, 2020.

[53] S. Chakrabarti, S. S. Chakrabarti, U. Kaur, B. K. Agrawal, U. Ganguly, and K. Jin, “Cross-immunity and trained immunity in explaining variable COVID-19 mortality-guidance for future pandemics,” *Journal of Medical Virology*, vol. 93, no. 7, pp. 4094–4096, 2021.

[54] P. R. Martins-Filho, L. C. Ferreira, L. Heimfarth, A. A. de Souza Araújo, and L. I. Quintans- Júnior, “Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials,” *The Lancet Regional Health – Americas*, vol. 2, Article ID 100062, 2021.

[55] P. Kamstrup, P. Sivapanal, J. Eklöf et al., “Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: a cohort study,” *International Journal of Infectious Diseases*, vol. 108, pp. 370–376, 2021.

[56] D. Altulea, S. Maassen, M. V. Baranov, and G. van den Bogaart, “What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology,” *Journal of Molecular Cell Biology*, vol. 13, no. 3, pp. 175–184, 2021.

[57] W. B. Grant, H. Lahore, S. L. McDonnell et al., “Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths,” *Nutrients*, vol. 12, no. 4, Article ID 988, 2020.

[58] J. L. Mansur, C. Tajer, M. Mariani, F. Inserra, L. Ferder, and A. Cavall, “Vitamin D status and clinical severity and in-flammation markers in pediatric COVID-19 patients: single-center experience from a pandemic hospital,” *European Journal of Pediatrics*, vol. 180, no. 8, pp. 2699–2705, 2021.

[59] D. O. Meltzer, T. J. Best, H. Zhang, T. Vokes, V. Arora, and J. Solway, “Association of vitamin D status and other clinical characteristics with COVID-19 test results,” *JAMA Network Open*, vol. 3, no. 9, Article ID e2019722, 2020.

[60] Z. Maghbooli, M. A. Sahraian, M. Ebrahimi et al., “Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/
Advances in Virology

PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review, "Therapeutic Advances in Respiratory Disease," vol. 6, no. 5, pp. 277–295, 2012.

[78] G. Shapira, N. Shomron, and D. Gurwitz, "Ethnic differences in alpha-1 antitrypsin deficiency allele frequencies may partially explain national differences in COVID-19 fatality rates," The FASEB Journal, vol. 34, no. 11, pp. 14160–14165, 2020.

[79] H. Yoshikura, "Epidemiological correlation between COVID-19 epidemic and prevalence of α-1 antitrypsin deficiency in the world," Global Health & Medicine, vol. 3, no. 2, pp. 73–81, 2021.

[80] I. Blanco, F. J. de Serres, E. Fernandez-Bustillo, B. Lara, and M. Miravitlles, "Estimated numbers and prevalence of PI*S and PI*Z alleles of 1-antitrypsin deficiency in European countries," European Respiratory Journal, vol. 27, no. 1, pp. 77–84, 2006.

[81] I. Blanco, F. J. de Serres, V. Carcaba, B. Lara, and E. Fernandez-Bustillo, "Alpha-1 antitrypsin deficiency PI*S and PI*S gene frequency distribution using on maps of the world by an inverse distance weighting (IDW) multivariate interpolation method," Hepatitis Monthly, vol. 12, no. 10 HCC, Article ID e7434, 2012.

[82] A. A. Mueller, T. Tamura, C. P. Crowley et al., "Inflammatory biomarker trends predict respiratory decline in COVID-19 patients," Cell Reports Medicine, vol. 1, no. 8, Article ID 100144, 2020.

[83] J. H. Ko, G. E. Park, J. Y. Lee et al., "Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients," Journal of Infection, vol. 73, no. 5, pp. 468–475, 2016.

[84] D. Vasileva and A. Badawi, "C-reactive protein as a biomarker of severe H1N1 influenza," Inflammation Research, vol. 68, no. 1, pp. 39–46, 2019.

[85] M. Sharifpour, S. Rangaraju, M. Liu et al., "C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19," PLoS One, vol. 15, no. 11, Article ID e0242400, 2020.

[86] A. Villoteau, M. Asfar, M. Otekpo, J. Loison, J. Gautier, and C. Annweiler, "Elevated C-reactive protein in early COVID-19 predicts worse survival among hospitalized geriatric patients," PLoS One, vol. 16, no. 9, Article ID e0256931, 2020.

[87] C. Tan, Y. Huang, F. Shi et al., "C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early," Journal of Medical Virology, vol. 92, no. 7, pp. 856–862, 2020.

[88] Q. Li, X. Ding, G. Xia et al., "Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study," EclinicalMedicine, vol. 23, pp. 100375–100377, 2020.

[89] K. El Aidaoui, A. Haoudar, M. Khalis et al., "Predictors of severity in COVID-19 patients in Casablanca, Morocco," Cureus, vol. 12, no. 9, Article ID e10716, 2020.

[90] J. Z. Kantri, M. Khalis, A. Haoudar et al., "Hematological and biochemical abnormalities associated with severe forms of COVID-19: a retrospective single center study from Morocco," PLoS One, vol. 16, no. 2, Article ID e0246295, 2021.

[91] A. S. Doghish, W. F. Elkhatab, E. A. Hassan et al., "Clinical characteristics of Egyptian male patients with COVID-19 acute respiratory distress syndrome," PLoS One, vol. 16, no. 4, Article ID e0249346, 2021.

[92] F. Fonseca and M. Izar, "High-sensitivity C-reactive protein and cardiovascular disease across countries and ethnicities," Clinics, vol. 71, no. 4, pp. 235–242, 2016.

[93] L. Lindesmith, C. Moe, S. Marionneau et al., "Human susceptibility and resistance to Norwalk virus infection," Nature Medicine, vol. 9, no. 5, pp. 548–553, 2003.

[94] T. Boren, P. Falk, K. A. Rohl, G. Larson, and S. Normark, "Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens," Science, vol. 262, no. 5141, pp. 1892–1895, 2003.

[95] Y. Cheng, G. Cheng, C. H. Hui et al., "ABO blood group and susceptibility to severe acute respiratory syndrome," Journal of American Medical Association, vol. 293, no. 12, pp. 1450–1452, 2005.

[96] S.-C. Wu, C. M. Arthur, J. Wang et al., "The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A," Blood Advances, vol. 5, no. 5, pp. 1305–1309, 2021.

[97] Y. Zhang, R. Garner, S. Salehi, M. La Roca, and D. Duncan, "Association between ABO blood types and coronavirus disease 2019 (COVID-19), genetic associations, and underlying molecular mechanisms: a literature review of 23 studies," Annals of Hematology, vol. 100, no. 5, pp. 1123–1132, 2021.

[98] L. Cooling, "Blood groups in infection and host susceptibility," Clinical Microbiology Reviews, vol. 28, no. 3, pp. 801–870, 2015.

[99] J. L. Anderson, H. T. May, S. Knight et al., "Association of sociodemographic factors and blood group type with risk of COVID-19 in a US population," JAMA Network Open, vol. 4, no. 4, Article ID e217429, 2021.

[100] R. Goel, E. M. Bloch, F. Pirenne et al., "ABO blood group and COVID-19: a review on behalf of the ISBT COVID-19 working group," Vox Sanginis, vol. 116, no. 8, pp. 849–861, 2021.

[101] M. Amdaadou, G. Arcuri, and N. Levratto, "Are regions equal in adversity? A spatial analysis of spread and dynamics of COVID-19 in Europe," The European Journal of Health Economics, vol. 22, no. 4, pp. 629–642, 2021.

[102] L. C. Zalla, C. L. Martin, J. K. Edwards, D. R. Gartner, and G. A. Noppert, "A geography of risk: structural racism and COVID-19 mortality in the United States," American Journal of Epidemiology, vol. 190, no. 8, pp. 1439–1446, 2021.

[103] A. M. Navar, S. N. Purinton, Q. Hou, R. J. Taylor, and E. D. Peterson, "The impact of race and ethnicity on outcomes in 19,584 adults hospitalized with COVID-19," PLoS One, vol. 16, no. 7, Article ID e0254809, 2020.

[104] G. Ogodege, J. Raveren, S. Adhikari et al., "Assessment of racial/ethnic disparities in hospitalization and mortality in patients with COVID-19 in New York city," JAMA Network Open, vol. 3, no. 12, Article ID e2026881, 2020.

[105] B. D. Renelus, N. K. Khoury, K. Chandrasekaran et al., "Racial disparities in COVID-19 hospitalization and in-hospital mortality at the height of the New York city pandemic," Journal of Racial and Ethnic Health Disparities, vol. 8, no. 5, pp. 1161–1167, 2021.

[106] W. Mude, V. M. Oguoma, T. Nyanhanda, L. Mwanri, and E. D. Peterson, "The impact of race and ethnicity on outcomes in 19,584 adults hospitalized with COVID-19," PLoS One, vol. 16, no. 7, Article ID e0254809, 2020.

[107] G. A. Noppert, "A geography of risk: structural racism and COVID-19 mortality in the United States," American Journal of Epidemiology, vol. 190, no. 8, pp. 1439–1446, 2021.

[108] E. D. Peterson, "The impact of race and ethnicity on outcomes in 19,584 adults hospitalized with COVID-19," PLoS One, vol. 16, no. 7, Article ID e0254809, 2020.
equitable and averts more deaths than age-based thresholds alone,” *Science Advances*, vol. 7, pp. 1–14, Article ID eabh2099, 2021.

[109] R. Mathur, C. T. Rentsch, C. E. Morton et al., “Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform,” *The Lancet*, vol. 397, no. 10286, pp. 1711–1724, 2021.

[110] S. Michalopoulos and E. Papaioannou, “On the ethnic origins of african development: chiefs and precolonial political centralization,” *Academy of Management Perspectives*, vol. 29, no. 1, pp. 32–71, 2015.

[111] NCD Risk Factor Collaboration (NCD-RisC)-Africa Working Group, A. P. Kengne, J. Bentham et al., “Trends in obesity and diabetes across Africa from 1980 to 2014: an analysis of pooled population-based studies,” *International Journal of Epidemiology*, vol. 46, no. 5, pp. 1421–1432, 2017.

[112] S. Pastakia, C. Pekny, S. Manyara, and L. Fischer, “Diabetes in sub-Saharan Africa—from policy to practice to progress: targeting the existing gaps for future care for diabetes,” *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, vol. 10, pp. 247–263, 2017.

[113] A. J. Price, A. C. Crampin, A. Amberbir et al., “Prevalence of obesity, hypertension, and diabetes, and cascade of care in sub-Saharan Africa: a cross-sectional, population-based study in rural and urban Malawi,” *Lancet Diabetes & Endocrinology*, vol. 6, no. 3, pp. 208–222, 2018.

[114] World Health Organization, “Tracking SARS-CoV-2 variants,” World Health Organization, Geneva, Switzerland, 2021, https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.

[115] N. D. Rochman, Y. I. Wolf, G. Faure, P. Mutz, F. Zhang, and E. V. Koonin, “Ongoing global and regional adaptive evolution of SARS-CoV-2,” *Proceedings of the National Academy of Sciences*, vol. 118, no. 29, Article ID e2104241118, 2021.

[116] E. A. Undurraga, G. Chowell, and K. Mizumoto, “COVID-19 case fatality risk by age and gender in a high testing setting in Latin America: Chile, March–August 2020,” *Infectious Diseases of Poverty*, vol. 10, no. 1, p. 11, 2021.

[117] W. Yang, S. Kandula, M. Huynh et al., “Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis,” *The Lancet Infectious Diseases*, vol. 21, no. 2, pp. 203–212, 2021.

[118] R. Pastor-Barriuso, B. Pérez-Gómez, M. A. Hernán et al., “Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study,” *BMJ*, vol. 371, Article ID m4509, 2020.

[119] M. S. Green, V. Peer, N. Schwartz, and D. Nitzan, “The confounded crude case-fatality rates (CFR) for COVID-19 hide more than they reveal—a comparison of age-specific and age-adjusted CFRs between seven countries,” *PLoS One*, vol. 15, no. 10, Article ID e0241031, 2020.

[120] H. Tegally, E. Wilkinson, M. Giovanetti et al., “Detection of a SARS-CoV-2 variant of concern in South Africa,” *Nature*, vol. 592, no. 7854, pp. 438–443, 2021.

[121] K. M. McCarthy, S. Tempia, T. Kufa et al., “The importation and establishment of community transmission of SARS-CoV-2 during the first eight weeks of the South African COVID-19 epidemic,” *EClinicalMedicine*, vol. 39, Article ID 101072, 2021.

[122] F. Zhang, H. Karamagi, N. Nsenga et al., “Predictors of COVID-19 epidemics in countries of the world health organization African region,” *Nature Medicine*, vol. 27, no. 11, pp. 2041–2047, 2021.